CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Oxervate (cenegermin-bkbj)

Coverage policy for Oxervate (cenegermin-bkbj) for members (Medicaid scope) specifying clinical criteria for approval, quantity limits, and duration for treatment of persistent epithelial defects/corneal ulceration related to neurotrophic keratitis.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyOxervate (cenegermin-bkbj)

Policy CodePolicy N/A

Change Typeclarified

Effective DateMay 1, 2019

Next Review Date

Key ActionAuthorization of 8 weeks may be granted only when all documented clinical criteria are met; provider must document age ≥2 years, prescriber specialty, refractory PED/corneal ulcer ≥2 weeks, decreased corneal sensitivity in at least one corneal quadrant, no prior Oxervate in affected eye, technique counseling, and confirmation of sufficient dexterity.

SourceLink

POLICY UPDATE CHANGES

Reviewed on 3/2026 with no material clinical policy statement changes indicated in document header.

8 weeksCoverage Duration

28 vialsQty per 28 days (one eye)

56 vialsQty per 28 days (both eyes)

≥2 yrsMinimum Age

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Scope: Coverage policy for Oxervate (cenegermin-bkbj) for members (Medicaid scope) for treatment of neurotrophic keratitis presenting as persistent epithelial defects (PED) or corneal ulceration. Coverage stance: covered_with_criteria. Product indication: Oxervate is indicated for neurotrophic keratitis presenting as persistent epithelial defects or corneal ulceration. Coverage duration: 8 weeks. Quantity limits: 28 vials per 28 days for one eye and 56 vials per 28 days if both eyes are affected. Minimum age for authorization: >=2 years. Policy effective date: 05/01/2019; last review: 03/01/2026.

OpenPayer

Oxervate (cenegermin-bkbj)

Coverage Summary